On October 22, 2025, the Korean Academy of Implant Dentistry (KAID) signed a Memorandum of Understanding (MOU) with the regenerative-medicine company ZERONE CELLVANE at the Andaz Seoul Hotel in Apgujeong.

This partnership aims to strengthen academic collaboration in research, education, and clinical applications involving polydeoxyribonucleotide (PDRN) and to promote innovation and growth within Korea’s regenerative dental-medicine industry.

ZERONE CELLVANE is recognized as one of only six global and five domestic companies specializing in PDRN technology. The company possesses an exclusive physical-shearing–based DNA refinement platform, which enables the production of highly uniform and finely fragmented DNA molecules, thereby maximizing bioactivity and therapeutic efficiency.

Through this agreement, ZERONE CELLVANE plans to expand joint clinical and translational research focused on evidence-based regenerative therapies utilizing PDRN. KAID, in turn, expects this collaboration—founded on ZERONE CELLVANE’s advanced technology and research expertise—to serve as a turning point for academic progress and industrial development in the field of dental regenerative science.

Following the signing ceremony, both organizations held a round-table discussion, during which they shared visions for the future of regenerative dentistry and reaffirmed their commitment to building a sustainable, long-term partnership that will continue to drive innovation in dental medicine.